Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Citius Oncology, Inc. (CTOR)

NCM · Drug Manufacturers - Specialty & Generic

$0.54-0.01 (-2.63%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$50.3M
P/E (TTM)
EPS
$-0.48
Div Yield
52W Range
$0.49–$2.37
Beta
3.48

Company overview

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Peers in Drug Manufacturers - Specialty & Generic

All in industry →

Recent press releases

Citius Oncology, Inc. has not issued a press release in this window.

SEC filings

All filings →

Citius Oncology, Inc. has not filed an SEC document in this window.

Citius Oncology, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
5,584,080 sh-27.3%
596,997 sh+231.3%
73,992 sh-41.7%
120,639 sh● NEW
220,047 sh+31.6%
104,500 sh● NEW
42,900 sh0.0%
23,515 sh● NEW

People at Citius Oncology, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
12/24
NI -$6.7M
03/25
NI -$7.7M
06/25
NI -$5.4M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.08
Prior: $-0.11
Revenue sparkline